Limited availability expected for horse joint drug
Published on
This article is more than 3 years old
A drug used to treat joint dysfunction and lameness in horses is expected to be in short supply or unavailable during factory renovations.
Luitpold Pharmaceuticals announced in May that the renovations at the company’s Shirley, N.Y., factory would affect production of Adequan i.m., the company’s polysulfated glycosaminoglycan solution. The company announced that the drug could be out of stock for a brief period, and Luitpold expects to resume shipping its 5-mL single-dose ampules in July and its 50-mL multidose vials in August.
The drug is used to treat noninfectious degenerative joint dysfunction and traumatic joint dysfunction in horses, according to the Food and Drug Administration.